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Background: Burning mouth syndrome is a poorly understood disease process with no current standard of treat-
ment. The goal of this article is to provide an evidence-based, practical, clinical algorithm as a guideline for the 
treatment of burning mouth syndrome.
Material and Methods: Using available evidence and clinical experience, a multi-step management algorithm was 
developed. A retrospective cohort study was then performed, following STROBE statement guidelines, comparing 
outcomes of patients who were managed using the algorithm and those who were managed without.
Results: Forty-seven patients were included in the study, with 21 (45%) managed using the algorithm and 26 (55%) 
managed without. The mean age overall was 60.4 ±16.5 years, and most patients (39, 83%) were female. Cohorts 
showed no statistical difference in age, sex, overall follow-up time, dysgeusia, geographic tongue, or psychiatric 
disorder; xerostomia, however, was significantly different, skewed toward the algorithm group.  Significantly more 
non-algorithm patients did not continue care (69% vs. 29%, p=0.001). The odds ratio of not continuing care for the 
non-algorithm group compared to the algorithm group was 5.6 [1.6, 19.8]. Improvement in pain was significantly 
more likely in the algorithm group (p=0.001), with an odds ratio of 27.5 [3.1, 242.0].
Conclusions: We present a basic clinical management algorithm for burning mouth syndrome which may increase 
the likelihood of pain improvement and patient follow-up.




Burning mouth syndrome (BMS), an idiopathic condi-
tion characterized by chronic oral mucosal burning and 
pain, afflicts between 0.7 and 7% of the population (1-
3). Often the disease occurs in peri- or post-menopausal 
women between 50 and 70 years of age (4). Symptoms 
of the disease include burning or itching of the oral mu-
cosa as well as dysgeusia, paresthesia, dysesthesia, and 
xerostomia (1). The BMS diagnosis is based on the ex-
clusion of any potential local or systemic causes of bur-
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ning mouth sensation. Notably, BMS is associated with 
psychiatric disorders such as depression and anxiety, 
which have been implicated in potential neuropsychia-
tric etiologies of the disease (3).
Symptoms of BMS are nonspecific and the diagnosis 
is often difficult to establish. Furthermore, there are no 
standard guidelines for management of BMS and phy-
sicians are left to employ whatever treatments they are 
comfortable and/or have experience with. Studies have 
not revealed any treatments that have been proven to be 
effective enough to be considered standard of care. The-
refore, we sought to address this lack of guidance by 
developing and testing an algorithm incorporating the 
various treatment strategies utilized in studies conduc-
ted over the last 20 years (5). Our goal was to achieve a 
balance of efficacy, risk, and practicality.
Material and Methods
Management Algorithm Development
This study was approved by the institutional review 
board from Loma Linda University Medical Center and 
appropriate consents were obtained. The development of 
the evidence- based treatment algorithm we used in this 
study is supported by the research conducted by Liu et 
al. Below is a summary of each step of the algorithm, 
which was founded on previous literature and supported 
by our recent systematic review (5). These steps were 
taken progressively to achieve adequate symptom con-
trol. A flowchart of the algorithm is presented in Figure 
1.
Step 1: Diagnosis of Primary BMS
- Thorough history and physical to differentiate from se-
condary causes of BMS, such as medication(s), fungal 
infection, and other mucosal diseases (6).
- Once primary BMS is established, start empiric B vita-
mins, folate, and/or antifungals (7,8).
Step 2: Patient Education
- Educate patients on nature of BMS and provide reas-
surance (9).
- Counsel relevant patients on possible relationship with 
menopause (10).
- Psychiatric screening and offer psychiatric referral if 
pertinent.
Step 3: Oral Hygiene Optimization
- Encourage oral hygiene standards per current Ameri-
can Dental Association recommendations, including (1) 
brushing teeth twice daily for two minutes each time, (2) 
tongue brushing, (3) daily flossing, and (4) regular den-
tal visits for professional cleaning and oral exams (11).
- Trial non-alcoholic mouthwashes and avoid foaming 
agents in toothpaste such as sodium lauryl sulfate (SLS).
- Prevent xerostomia by promoting adequate fluid in-
take; avoidance of alcohol, tobacco, overly salty foods, 
acidic beverages, and consumption of sugar-rich foods 
(12).
Step 4: Alpha-lipoic Acid Supplementation
- ALA trial regimen of 600mg/day for 3-4 months with 
consideration for treatment extension if improvement 
but relapse in symptoms after discontinuation (13).
- If symptoms fail to improve sufficiently, gabapentin or 
psychotherapy may be added, as both have been shown 
to work synergistically with ALA (5).
Step 5: Prescription Oral Topical Medications
- Trial of daily chlorhexidine gluconate (14).
-Increase salivary flow with over-the-counter artificial 
saliva (lozenges, rinses, sprays, and swabs) and siala-
gogues (sugarless gum/lozenges, muscarinic agonists) 
(15).
Step 6: Neuropathic Treatments
- Clonazepam can be used topically using 1 mg tablets 
held intraorally near the sites of pain for 3 minutes wi-
Fig. 1: Burning mouth syndrome management algorithm flowchart.
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thout swallowing, followed by expectoration, three ti-
mes a day (16).
- Gabapentin may also be considered, starting at 300mg/
day, with gradual titration up to 2400mg/day if neces-
sary (17).
- Consider neurology consultation for long-term use and 
titration due to potential adverse neurologic effects with 
extended use.
Step 7: Psychiatric Consultation and Treatment
- Patients are usually not initially inclined to obtain psy-
chiatric consultation. It may be offered again at this time 
given multiple treatment failures. 
- Consider psychotherapy.(5)
Step 8: Systemic Clonazepam
- Trial clonazepam 0.5 mg daily for 9 weeks (18).
- Consider psychiatry consultation for long-term use.
Step 9: Treatment of Refractory BMS
- Consider antidepressants in patients with comorbid 
psychiatric disease (3).
- Consider hormone replacement therapy (HRT) along 
with consultation with women’s health (10).
- Consider less-studied and equivocal modalities such 
as benzydamine hydrochloride oral rinse (19), sucralfate 
oral rinse (20), topical capsaicin rinse (21), catuama her-
bal supplementation (22), acupuncture (23), or lycopene 
enriched olive oil (24).
Analysis of Algorithm Effectiveness
A retrospective cohort study was conducted for 2013 
to 2016 comparing all patients who underwent BMS 
management using the algorithm described above with 
those who did not. The STROBE Initiative statement 
was followed (25).  All patients were tertiary consults 
to the Department of Otolaryngology and were treated 
using the algorithm or without a specific algorithm in 
accordance with consultants own training and knowle-
dge. Patient records were obtained from a broad elec-
tronic medical record review using the broad diagnostic 
codes such as 529.6 (glossodynia) and 529.1 (geogra-
phic tongue), as there is no formal “burning mouth sy-
ndrome” code. The patient’s charts were then reviewed 
to ensure that the patients met the literature or research 
definition of primary BMS criteria previously outlined 
in the introduction. All patients diagnosed with primary 
BMS were included for analysis.  Pain was evaluated by 
documentation of patient pain in the subjective history 
section and the nursing documentation.  Demographics 
and BMS related data were extracted and patient groups 
were analyzed.  Bias was addressed by having two inde-
pendent reviews (Y.K. and T.Y.) of the patient charts and 
data collection with discrepancies resolved by a third in-
dependent review from the senior author (J.I.). 
The two-tailed, unequal variance, Student t-test and Fi-
sher exact test were used where appropriate to compare 
groups. Means are reported as mean ±standard deviation 
(SD). Odds ratios (OR) and confidence intervals (CI) are 
reported as OR [lower 95% CI, upper 95 % CI]. Signifi-
cance was established at the p<0.05 level (sample sizes 
were adequately powered, beta 0.2, to achieve improved 
pain versus no change pain differences and for continued 
follow-up on the algorithm versus did not follow-up).  
Results
A total of 47 patients were met the appropriate criteria 
and were diagnosed with primary BMS. Of those pa-
tients, 21 (45%) were managed using the algorithm and 
26 (55%) were not. Patient characteristics are presented 
in Table 1. The mean age overall was 60.4 ±16.5 years, 
and most patients (39, 83%) were female, 8 or 17% were 
male. The algorithm group was not significantly diffe-
rent from the non-algorithm groups in terms of age, sex, 
or follow-up time. However, significantly more algo-
rithm patients had xerostomia (62% vs. 8%, p<0.001), 
and significantly more non-algorithm patients did not 
continue care (69% vs. 29%, p=0.001). The OR of not 
continuing care for the non-algorithm group compared 
to the algorithm group was 5.6 [1.6, 19.8].
Improvement in pain was significantly more likely in the 
algorithm group (p=0.001). The distribution of pain out-
comes is shown in Table 2. The OR of experiencing an 
improvement in pain after undergoing the algorithm-ba-
sed management versus the non-algorithm management 
was 27.5 [3.1, 242.0].
Discussion
Burning mouth syndrome is a poorly understood con-
dition that frustrates both the patient and the physician. 
Treatments are varied and no one modality stands above 
the rest (5,26). Moreover, initial treatments are often in-
effective and evidence shows that this disease is a chro-
nic pain disorder with a highly variable treatment cour-
se.  No standardized treatments or guidelines exist, and 
as such, BMS is a very difficult disorder to treat with its 
primary symptom being one of chronic pain. This was 
the impetus for our research, to use the existing knowle-
dge of treatment efficacy to develop a pragmatic, clini-
cally useful management algorithm.
The underlying principle of our algorithm was essentia-
lly to rank treatment modalities by balancing efficacy 
with adverse effects and accessibility by using the best 
available evidence and the literature and clinical expe-
rience (5). It is a stepwise ladder that starts with proper 
diagnosis and ends with management of refractory ca-
ses. It is important to note that the order in which we pla-
ced different therapies on the ladder was based primarily 
on evidence from RCTs, then other evidence levels in 
the literature, and lastly on our own experience. There-
fore, other physicians, dentists, and oral health providers 
may have differing opinions about which treatments be-
long where on the timeline of treatment. Furthermore, 
clinicians may have anecdotal evidence from their own 
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Local  
1. Local irritation from poor-fitting denture 
2. Dental surgery 
3. Oral trauma 
4. Parafunctional habits: bruxism, tongue posturing 
5. Allergic contact stomatitis from dental prosthetic material, foods, oral care products 
6. Xerostomia due to aging, radiotherapy, salivary gland disorders, drugs 
7. Infectious: fungal, bacterial, viral 
8. Oral lesions: lichen planus, migratory glossitis, geographic tongue, bullous pemphigoid, pemphigus vulgaris, 
herpetic lingual neuralgia 
Systemic  
        1.     Endocrine disorders: diabetes, thyroid disorders 
        2.     Nutritional deficiencies: iron, zinc, folate, vitamin B1, B2, B6, B12 
3. Hyposalivation: sicca syndrome, Sjorgen syndrome, connective tissue diseases 
4. Drugs: ACE inhibitors, antihyperglycemics, antihistamines, antiretrovirals, neuroleptics, chemotherapeutic agents, 
benzodiazepines 




3. Obsessive-compulsive disorder 
4. Somatoform disorder 
5. Cancer phobia 






        1.     Oral neoplasms or cancers 
2. Acoustic neuroma 
 
Table 1: Secondary, contributory, or associated causes of burning mouth syndrome (3).
  Mean ±SD or Number (%) p 
All patients (n=47) Algorithm (n=21) Non-algorithm (n=26) 
Age 60.4 ±16.5 62.0 ±10.5 60.9 ±19.3 0.864 
Male 8 (17) 3 (14) 5 (19) 0.715 
Female 39 (83) 18 (86) 21 (81) 
Follow-up (months) 29.0 ±21.8 24.5 ±21.5 34.9 ±20.4 0.289 
Dysgeusia 14 (30) 8 (38) 6 (23) 0.342 
Geographic tongue 17 (36) 11 (52) 6 (23) 0.066 
Psychiatric disorder 18 (38) 11 (52) 7 (27) 0.13 
Lost to follow-up 23 (49) 6 (29) 18 (69) 0.001 
Improved 12 (26) 10 (48) 1 (4) 
No change 11 (23) 5 (24) 6 (23) 
Worsened 1 (2) 0 (0) 1 (4) 
  
Table 2: Patient characteristics and distribution of outcomes comparing patients managed with the algorithm and those man-
aged without. P-values indicate comparison between the algorithm and non-algorithm groups. The last four rows indicate 
change in pain/burning symptoms from first to last visit.
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experience to reposition certain treatments or even add 
in other modalities. In treating this complex, frustrating, 
and multifactorial chronic disease while going through 
the algorithm, it is usually helpful to consider consulta-
tions with other specialties, such as primary care, psy-
chiatry, dentistry, and women’s health to obtain assistan-
ce with medication usage, counseling, and other aspects 
of management. The exact timing at which consultations 
are obtained is less important than delivery of adequate 
care such that patients have sufficient support to unders-
tand and continue managing their own illness.
Another principle we attempted to follow in our algori-
thm was to incorporate different classes of medications/
therapies to tackle the symptomatic presentation in each 
BMS patient, as opposed to using 2 or 3 treatments (e.g. 
antifungals, vitamins, prescription mouthwashes) for 
every patient that is typical of non-algorithmic approa-
ches.
We found a significant difference in the rate of impro-
vement in patients who underwent the algorithmic ma-
nagement (48%) from those who did not (4%). Overall, 
patients in our study were similar to those found in the 
literature, with a majority of perimenopausal females 
and symptom/comorbidity frequencies similar to that 
found in other studies (10). The baseline characteristics 
of the 2 cohorts were similar except for the rate of xeros-
tomia.  We found that unless xerostomia was specifically 
questioned by the physician it most often was left out 
of patient subjective history component of the presen-
tation, possibly due to the focus on the pain component 
of this disease process.  We found, when xerostomia 
was specifically screened that it was more prevalent in 
the algorithm group (62% vs. 8%). This actually lends 
support to our management algorithm’s success in that 
patients with xerostomia are typically more difficult to 
treat when it is an associated finding in BMS pain.  Xe-
rostomia is a comorbid sign and symptom, if recognized, 
in subsets of BMS cohorts, and is present when directly 
studied in 46-67% of patients. One explanation for this 
difference is that the presence of xerostomia may not 
have been recognized in the non-algorithm group—as it 
was not directly elicited and was only documented when 
it was a patient complaint—whereas it was routinely as-
ked in the algorithm group with the help of the patient 
history survey we use, which was discussed earlier in 
the methods.  Further standardized prospective studies 
will help better delineate associated findings, like xeros-
tomia, and their effect on BMS symptom severity and on 
treatment response; however, in order to establish these 
studies, physicians and researchers need to standardize 
patient symptom and sign collection relevant to BMS 
patients specifically (5).
There was significantly more attrition in the non-algori-
thm group, with 69% of patients failing to continue care 
compared to 29% in the algorithm group. This may be 
due to better patient education in the algorithm group 
which strengthens the patient-physician relationship and 
reduces “doctor shopping.” We want to emphasize that 
indeed, treating BMS is a time-consuming and drawn-
out process, given the natural history of the disease and 
its progression over months to years (3).  Patients, by 
natural history of this chronic disease process, will li-
kely have symptoms for years and, moreover, treatment 
success requires optimization of co-morbid symptoms 
and frequently “trials” of medications over time.  Thus, 
an expectation for follow up and setting a follow-up 
schedule would be consistent with management of this 
chronic disorder.  We have attempted to limit attrition 
by using our standardized patient education tool which 
was discussed earlier in the methods and by ensuring 
follow-up appointments for symptom assessment and 
treatment response are planned out in regular time in-
tervals, similar to other chronic pain syndromes or spec-
trums of disease.
Our study is limited by the number of total patients; 
however, it compares favorably to the existing literatu-
re cohorts of BMS patients.  Another limitation is the 
number of patients who failed to continue care under 
our practice, a consistent finding in chronic pain pa-
tients. Prospective, clinical treatment strategies, empha-
sizing follow up through patient education and stepwise 
treatment trials are needed in this chronic pain disorder. 
There are intrinsic biases with retrospective studies and 
prospective trials with a stepwise treatment foundation 
would be of benefit.  Acknowledging this study’s limi-
tations, we hope this basic algorithm would serve as a 
practical start to the development of more comprehen-
sive management guides. With the advent of new me-
dications, stronger studies, and better understanding of 
this chronic pain disease process we propose a more 
algorithmic approach focusing on a stepwise treatment 
strategy and emphasizing proper patient education and 
follow-up.
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